New minimally invasive option available for patients with mitral valve disorders

Patients at a high risk for surgery with moderate to severe mitral regurgitation, severe mitral stenosis or moderate mixed mitral valve disease have a new, minimally invasive option at the Vanderbilt Heart and Vascular Institute (VHVI). Starting in June, VHVI began implantations of the M3 device, the first Food and Drug Administration-approved transseptal transcatheter mitral valve replacement.